Biogen (BIIB) is a biotechnology company founded by several notable scientists, two Nobel Prize recipients and one knighted. Biogen gained prominence during the late 90's for FDA and European approval of the interferon Avonex for the treatment of relapsing forms of multiple sclerosis (MS'), and rituximab for certain types of B-cell Non-Hodgkin's lymphoma; rituximab is the first monoclonal antibody therapy to be approved for a type of cancer. The FDA eventually approved rituximab for treatment of rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's granulomatosis), microscopic polyangiitis and chronic lymphocytic leukemia.